Using the DCA® Microalbumin/Creatinine (ACR) urine test on the DCA Vantage® Analyzer puts your practice on the front line of early kidney disease detection in patients with diabetes. ACR testing is recommended as an initial screening test for early detection of kidney disease by ADA, NKF, KDOQI and KDIGO. The ADA recommends testing ACR annually in patients with type 1 diabetes (with diabetes duration >5 years) and in patients with type 2 diabetes.
Quantitative microalbumin/creatinine ratio (ACR) test results in minutes
